PetVivo (PETV) Q3 2026 earnings summary

Executive summary

• Achieved significant progress in strategic alliances, product launches, and platform advancements, including the launch of PetVivo AI and AgenticPet, focusing on high-growth opportunities and recurring revenue streams.

• Expanded partnerships with Digital Landia, Veterinary Growth Partners, and Piezo BioMembrane, advancing R&D and commercialization efforts.

• Entered new international markets, including the UK, Mexico, and Canada, with regulatory milestones and initial shipments.

• Focused on commercializing and licensing veterinary medical devices, with Spryng and PrecisePRP as key products targeting osteoarthritis in dogs and horses.

• Operates as a single segment, with a pipeline of additional animal health products and 19 patents protecting its technology.

Financial highlights

• Nine-month revenues ended December 31, 2025, totaled $887,000, down 2% year-over-year, with a shift in sales mix toward PrecisePRP.

• Gross profit for nine months was $551,500 (62.2% of revenues), down from $812,130 and 89% margin last year due to lower-margin PrecisePRP sales.

• Operating expenses decreased 2% to $6.7 million, reflecting cost reduction initiatives, while quarterly operating expenses were $2,336,167, up slightly year-over-year.

• Operating loss for nine months was $6.1 million; net loss was $7.5 million (27 cents/share) vs. $6 million (30 cents/share) prior year.

• Net cash used in operations was $5.3 million, mainly for inventory build and payables reduction.

Outlook and guidance

• Expect continued sales momentum and market penetration in fiscal 2026 and beyond, with new product launches and expanded sales efforts.

• No formal revenue or P&L guidance provided for the coming year; management is not issuing specific forecasts.

• Management expects continued need for additional capital to support commercialization and ongoing operations.

• Anticipate revenue from Digital Landia partnership to begin in the next fiscal year.